Underuse of key guideline-indicated therapies in vulnerable ACS populations (elderly, advanced renal disease) may contribute to excess mortality.
Underuse of indicated ACS therapies in elderly and renal patients may drive excess mortality; leaves open whether targeting disparities improves outcomes.
Variations exist in the provision of indicated care to patients with ACS according to age, diabetic status, renal function and type of admitting hospital. Excess mortality in elderly patients and in those with advanced renal disease may be partially attributable to failure to use key therapies.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: